In contrast to this, new research has shown that CDK4/6 inhibition may support tumour immune evasion in a number of tumour types through the increase of the immunosuppressive programmed cell death protein 1 ligand (PD-L1) expression on tumour cells. This evidence concerns the gene CDK4 and neoplasm.